Senseonics Holdings Inc. (NASDAQ: SENS) announced the pricing of an underwritten public offering consisting of 8 million shares of common stock at $5.00 per share and pre-funded warrants to purchase 8 million shares at $4.999 per warrant.

The medical technology company expects gross proceeds of $80 million before deducting underwriting discounts, commissions and estimated offering expenses. The company also granted underwriters a 30-day option to purchase up to an additional 2.4 million shares at the public offering price, less underwriting discounts and commissions.

The offering is expected to close on May 4, 2026, subject to customary closing conditions. The pre-funded warrants will not be listed on any securities exchange.

TD Cowen and Barclays are serving as joint book-running managers for the offering, while Mizuho and Lake Street are acting as bookrunners.

Senseonics stated it intends to use the net proceeds to fund the ongoing launch of its Eversense 365 product and continued development of pipeline products, as well as for working capital and general corporate purposes.

The offering is being conducted under a shelf registration statement on Form S-3 that became effective with the Securities and Exchange Commission on August 18, 2025. Senseonics develops implantable continuous glucose monitoring systems for people with diabetes.